{
  "id": "6025a45b1cb411341a0000b5",
  "type": "list",
  "question": "List 4 targeted synthetic DMARDs that are JAK inhibitors.",
  "ideal_answer": "Targeted synthetic (ts) DMARDs that are Janus kinase (JAK) inhibitors include tofacitinib, baricitinib, filgotinib, upadacitinib.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31969328"
  ],
  "snippets": [
    {
      "text": "The task force agreed on 5 overarching principles and 12 recommendations concerning use of conventional synthetic (cs) DMARDs (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GCs); biological (b) DMARDs (tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, sarilumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (the Janus kinase (JAK) inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31969328",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RESULTS: The task force agreed on 5 overarching principles and 12 recommendations concerning use of conventional synthetic (cs) DMARDs (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GCs); biological (b) DMARDs (tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, sarilumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (the Janus kinase (JAK) inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31969328",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "tofacitinib, baricitinib, filgotinib, upadacitinib"
}